Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

sandoz s.r.o., praha array - 4988 pentahydrÁt ceftazidimu - prášek pro injekční roztok - 500mg - ceftazidim

Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

sandoz s.r.o., praha array - 4988 pentahydrÁt ceftazidimu - prášek pro injekční roztok - 1g - ceftazidim

Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

sandoz s.r.o., praha array - 4988 pentahydrÁt ceftazidimu - prášek pro injekční/infuzní roztok - 2g - ceftazidim

Den europeiske union - tsjekkisk - EMA (European Medicines Agency)

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - antineoplastická činidla - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ceftazidime pentahydrate, quantity: 2.328 g (equivalent: ceftazidime, qty 2 g) - injection, powder for - excipient ingredients: sodium carbonate - fortum is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials , but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns. respiratory tract infections: for example, pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis. severe ear, nose and throat infections: for example, otitis media, mastoiditis. urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. skin and soft tissue infections: for example, erys

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - enfortumab vedotin, quantity: 30 mg - injection, powder for - excipient ingredients: polysorbate 20; histidine hydrochloride monohydrate; histidine; trehalose dihydrate - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand-1 inhibitor.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - enfortumab vedotin, quantity: 20 mg - injection, powder for - excipient ingredients: polysorbate 20; trehalose dihydrate; histidine; histidine hydrochloride monohydrate - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand-1 inhibitor.

Israel - engelsk - Ministry of Health

astellas pharma international b.v., israel - enfortumab vedotin - powder for concentrate for solution for infusion - enfortumab vedotin 20 mg/vial - enfortumab vedotin - padcev is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (muc) who: - have previously received a programmed death receptor-1 (pd-1) or programmed death-ligand 1 (pd-l1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting or:- are ineligible for cisplatin-containing chemotherapy and have previously received a pd-1/pd-l1 inhibitor.

Israel - engelsk - Ministry of Health

astellas pharma international b.v., israel - enfortumab vedotin - powder for concentrate for solution for infusion - enfortumab vedotin 30 mg/vial - enfortumab vedotin - padcev is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (muc) who: - have previously received a programmed death receptor-1 (pd-1) or programmed death-ligand 1 (pd-l1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting or:- are ineligible for cisplatin-containing chemotherapy and have previously received a pd-1/pd-l1 inhibitor.

Israel - engelsk - Ministry of Health

novartis israel ltd., israel - ceftazidime as pentahydrate - powder for solution for inj/inf - ceftazidime as pentahydrate 2 g/vial - ceftazidime - ceftazidime - fortum is indicated for the treatment of the infections listed below in adults and children including neonates (from birth).• nosocomial pneumonia• broncho-pulmonary infections in cystic fibrosis• bacterial meningitis• chronic suppurative otitis media• malignant otitis externa• complicated urinary tract infections• complicated skin and soft tissue infections• complicated intra-abdominal infections• bone and joint infections• peritonitis associated with dialysis in patient on capd.treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing trans-urethral resection of the prostate (turp).the selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic gram negative bacteria.ceftazidime should be co-administered with other antibacterial agents whenever the possible range of causive bacteria would not fall within its spectrum of activity.consideration should be given to official guidelines on the appropriate use of antibacterial agents.